A 2026 review proposes that SFRP4 may inhibit tumor angiogenesis through integrin-linked disruption of Wnt–β-catenin ...
OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative ...
Arcus Biosciences casdatifan combinations showed superior or competitive PFS and response rates versus historical benchmarks.
A mouse study found that endothelial FoxO1 supports capillary remodeling, mitochondrial integrity and metabolic health in ...
PD-1 bispecific antibodies combine checkpoint blockade with CTLA-4 or VEGF targeting. Can one engineered molecule offer ...
CROWN ctDNA data link early lorlatinib progression to genomic complexity, TP53 and bypass pathways rather than new ALK ...
EyePoint thanks its employees affected by these measures for their dedication and contributions to the Company’s mission. Although today’s clinical setback highlights the challenges of drug ...
LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement – – Key secondary ...
An experimental treatment containing two naturally occurring pancreatic enzymes may be able to reduce the growth of cancer, a ...
From polynucleotides to exosomes, explore six tissue repair technologies, their potential benefits & the limits of current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results